Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Serotonin Syndrome × Octreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 11 Neoplasms 8 Diarrhea 6 Colorectal Neoplasms 6 Carcinoma, Hepatocellular 6 Carcinoid Tumor 6 Breast Neoplasms 5 Vipoma 4 Stomach Neoplasms 4 Somatostatinoma 4 Rectal Neoplasms 4 Insulinoma 4 Glucagonoma 4 Esophageal Neoplasms 4 Carcinoma, Islet Cell 4 Adenoma, Islet Cell 4 Weight Loss 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Intestinal Obstruction 3 Gastro-enteropancreatic neuroendocrine tumor 3 Gastrinoma 3 Colonic Neoplasms 3 Carcinoma 3 Acromegaly 3 Thymoma 2 Ovarian Neoplasms 2 Meningioma 2 Malnutrition 2

Interventions

telotristat ethyl 5 lanreotide 2 telotristat 1 pasireotide 1 lutetium Lu 177 dotatate 1 alpha-methyltryptophan 1 Receptor-Like Protein Tyrosine Phosphatases, Class 2 1 Random Allocation 1 Panitumumab 1 Octreotide 1 Magnetic Resonance Spectroscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04140409 2019-10-25

SCIROCCO

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 4 Terminated

Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡